<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>330</ReferenceId>
        <Keywords>changes made</Keywords>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15158608</PubmedId>
            <Abstract>Based on the fact that the 24 amino acid extracellular domain of M2 protein (M2e) is nearly invariant in all influenza A strains, several different M2e vaccine constructs and vaccination modalities have been developed by others and us. Although most of these vaccines could induce efficient and broad-spectrum immunity inhibiting influenza A virus infection in mice model, information of the refined protective epitope on M2e was scarce. In this paper, two M2e specific monoclonal antibodies (mAbs) conferring protective immunity in vivo were reported, which in passive administration could protect 75% mice from five LD(50) (50% lethal dose) challenge of influenza virus A/PR/8/34. In addition, higher M2e specific antibody titer (over 1:1600) could be detected after 12h of intraperitoneal passive administration in mice sera. Peptide mapping assay indicated that both mAbs strongly interacted with N-terminus and middle part peptides of M2e (NM2, aa2-12; MM2, aa8-18), but not with the C-terminus peptide (CM2, aa13-24). More importantly, M2e specific mAbs could recognize EVETPIRN (aa6-13) peptide, which were the overlapping region of NM2 and MM2 peptide and the neighboring amino acid residues. In contrast, M2e domain that was deleted EVETPIR sequence could not be recognized by either mAb in immunoblotting assay. All these results indicated that the epitope EVETPIRN (aa6-13) on M2e could be responsible for the induction of the protective immunity.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>131-6</ArticlePages>
            <ArticleTitle>Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Liu</LastName>
                    <ForeName>Wanli</ForeName>
                </Author>
                <Author>
                    <LastName>Zou</LastName>
                    <ForeName>Peng</ForeName>
                </Author>
                <Author>
                    <LastName>Chen</LastName>
                    <ForeName>Ying-Hua</ForeName>
                </Author>
            </Authors>
            <Affiliations>Laboratory of Immunology, Department of Biology, Protein Science Laboratory of MOE, Tsinghua University, The New Biological Building, Room 231, Beijing 100084, PR China.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Epitopes;M2 protein, Influenza A virus;Oligopeptides;Peptide Fragments;Recombinant Fusion Proteins;Viral Matrix Proteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Sequence; Animals; Antibodies, Monoclonal(blood; immunology); Blotting, Western; Body Weight; Cell Line; Dogs; Enzyme-Linked Immunosorbent Assay; Epithelial Cells(immunology; virology); Epitope Mapping; Epitopes(immunology); Female; Flow Cytometry; Immunization, Passive; Infections(immunology; virology); Influenza A virus(immunology); Mice; Mice, Inbred BALB C; Molecular Sequence Data; Oligopeptides(chemical synthesis; immunology); Orthomyxoviridae Infections(prevention &amp; control); Peptide Fragments(chemical synthesis; immunology); Recombinant Fusion Proteins(genetics; immunology); Survival Rate; Viral Matrix Proteins(chemistry; immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>93</Volume>
                <Issue>2-3</Issue>
                <Title>Immunology letters</Title>
                <Issn>0165-2478</Issn>
                <MedlineTa>Immunol Lett</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>LM2</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>EVETPIRN</LinearSequence>
                        <StartingPosition>6</StartingPosition>
                        <EndingPosition>13</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P06821.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>14686</EpitopeId>
                <ReferenceStartingPosition>6</ReferenceStartingPosition>
                <ReferenceEndingPosition>13</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>M2e specific antibodies were shown to protect lethal influenza A virus challenge by passive transfer.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 3B and 4B</LocationOfData>
                        <BCellId>16828</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SLLTEVETPIRNEWGCRCNGSSD</LinearSequence>
                                            <StartingPosition>2</StartingPosition>
                                            <EndingPosition>24</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P06821.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M2e (2-24)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC240127</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>562</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mouse myeloma cells (SP2/0) were fused with spleen cells from immunized mice. Immunogen was built by  fusing GST to M2e peptide by a N-terminal K residue added to the peptide at synthesis. M2e specific mAb secreting hybridomas were screened by M2e peptide.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope was identified by testing overlapping peptides encompassing the extracelular domain of the M2 protein. This was defined as the  overlapping region between the positive peptides. The EVETPIRN peptide was synthetyzed and shown to be recongized by ELISA. Also, GSTM2e dsuien proteins with the epitopic sequence deleted fail to be recognized by WB by these mAbs.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>8C6, 1B12</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>LM2</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>EVETPIRN</LinearSequence>
                                        <StartingPosition>6</StartingPosition>
                                        <EndingPosition>13</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P06821.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1B</LocationOfData>
                        <BCellId>16827</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>SLLTEVETPIRNEWGCRCNGSSD</LinearSequence>
                                            <StartingPosition>2</StartingPosition>
                                            <EndingPosition>24</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P06821.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>M2e (2-24)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Protein conjugate</ComplexType>
                                        <PeptideModifications/>
                                        <SourceMolecule>
                                            <IedbAccession>SRC240127</IedbAccession>
                                        </SourceMolecule>
                                        <MoleculeSourceOrganismId>562</MoleculeSourceOrganismId>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mouse myeloma cells (SP2/0) were fused with spleen cells from immunized mice. Immunogen was built by  fusing GST to M2e peptide by a N-terminal K residue added to the peptide at synthesis. M2e specific mAb secreting hybridomas were screened by M2e peptide.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>139</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Monoclonal antibodies raised against the 2-24 fragment of M2 protein, and shown to be directed to this epitope, specifically label the surface of MDCK cells (Madin-Darby canine kidney) infected by influenza A virus PR8. Binding of M2e specific mAbs to M2e peptide in a dose-dependent manner was shown by ELISA. These mAbs show protective capacity at lethal viral infections upon adoptive transfer to naive Balb/c mice.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>8C6, 1B12</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Influenza A virus (A/Puerto Rico/8/34(H1N1))</AntigenReferenceName>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

